Alan S. Cross. (2023) Hit ‘em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target. Microbiology and Molecular Biology Reviews.
Crossref
Alan S. Cross, Nancy Greenberg, Melissa Billington, Lei Zhang, Christopher DeFilippi, Ryan C. May & Kanwaldeep K. Bajwa. (2015) Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis. Vaccine 33:48, pages 6719-6726.
Crossref
Siyuan Ma & Yaping Zhang. (2010) Preparation of Immunoglobulin Y (IgY) Against Lipopolysaccharide using Gel Chromatography from the Yolks of Eggs Laid by Immunized Hens. The Protein Journal 29:7, pages 475-480.
Crossref
Alan S. Cross. 2010. Endotoxins: Structure, Function and Recognition. Endotoxins: Structure, Function and Recognition
285
302
.
Alan S Cross, Steven Opal, Pamela Cook, Joseph Drabick & Apurba Bhattacharjee. (2004) Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 22:7, pages 812-817.
Crossref
Robert Stephens & Colin Hamilton-Davies. (2000) Update on antiendotoxin therapies. Hospital Medicine 61:4, pages 254-258.
Crossref
G. Berlot, U. Lucangelo & A. Gullo. 2000. Sepsis and Organ Dysfunction. Sepsis and Organ Dysfunction
17
33
.
Alan S. Cross, Steven M. Opal, Apurba K. Bhattacharjee, Sam T. Donta, Peter N. Peduzzi, Emil Fürer, John U. Que & Stanley J. CryzJrJr. (1999) Immunotherapy of sepsis: flawed concept or faulty implementation?. Vaccine 17, pages S13-S21.
Crossref
Apurba K. Bhattacharjee & Alan S. Cross. (1999) VACCINES AND ANTIBODIES IN THE PREVENTION AND TREATMENT OF SEPSIS. Infectious Disease Clinics of North America 13:2, pages 355-369.
Crossref
A. Gullo & G. Berlot. 1999. Sepsis and Organ Dysfunction. Sepsis and Organ Dysfunction
83
93
.
G. Berlot, L. Silvestri, F. Iscra, G. Sganga & A. Gullo. 1998. Sepsis and Organ Dysfunction. Sepsis and Organ Dysfunction
167
188
.
K. Werdan & G. Pilz. 1996. Intensivtherapie bei Sepsis und Multiorganversagen. Intensivtherapie bei Sepsis und Multiorganversagen
87
123
.
C. Martin, X. Viviand & F. Potié. 1996. Yearbook of Intensive Care and Emergency Medicine. Yearbook of Intensive Care and Emergency Medicine
177
193
.
A.S. Cross & S. Opal. (2016) Minireview: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?. Journal of Endotoxin Research 1:1, pages 57-69.
Crossref
David A Talan. (1993) Recent developments in our understanding of sepsis: Evaluation of anti-endotoxin antibodies and biological response modifiers. Annals of Emergency Medicine 22:12, pages 1871-1890.
Crossref
ANDERS FOMSGAARD & IAN ALAN HOLDER. (1993) Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS 101:1-6, pages 229-234.
Crossref
K. Werdan & G. Pilz. 1993. Intensivtherapie bei Sepsis und Multiorganversagen. Intensivtherapie bei Sepsis und Multiorganversagen
59
90
.
John Ludbrook. (1992) NEW THERAPIES FOR SHOCK ASSOCIATED WITH GRAM-NEGATIVE SEPSIS?. ANZ Journal of Surgery 62:12, pages 913-915.
Crossref
R DaifukuK HaenftlingJ YoungE S GrovesC TurrellF J Meyers. (1992) Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. Antimicrobial Agents and Chemotherapy 36:10, pages 2349-2351.
Crossref
Craig S. Rock & Stephen F. Lowry. (1991) Tumor necrosis factor-α. Journal of Surgical Research 51:5, pages 434-445.
Crossref
Poduri N. Rao, Daud A. Dube, Nigel C. Weightman, Beryl A. Oppenheim & Julie Morris. (1991) Prediction of Septicemia Following Endourological Manipulation for Stones in the Upper Urinary Tract. Journal of Urology 146:4, pages 955-960.
Crossref
Ruurd Torensma & Ad Fluit. (1991) Mechanism for monoclonal antibody mediated treatment of gram-negative shock. The Lancet 338:8760, pages 186.
Crossref
G. Pilz, S. Kääb, K. Werdan, Gertraud Neeser, Isolde Class, Ursula Schweigart, A. Brähler, O. Bujdoso & Roswita Neumann. (1991) Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock — An observational study as a prerequisite for placebo-controlled clinical trialsAdditive Immunglobulin-Therapie (ivIgG) bei 163 Patienten mit Sepsis und septischem Shock — eine Fallbeobachtungsstudie als Voraussetzung für plazebokontrollierte klinische Studien. Infection 19:4, pages 216-227.
Crossref
Günter Pilz, Thomas Gurniak, Oskar Bujdoso & Karl Werdan. (1991) A basic program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Computers in Biology and Medicine 21:3, pages 143-159.
Crossref
G. Pilz, I. Class, P. Boekstegers, A. Pfeifer, U. Müller & K. Werdan. 1991. Infektionen auf Intensivstationen. Infektionen auf Intensivstationen
139
154
.
G. Pilz & K. Werdan. (1990) Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shockHerz-Kreislauf-Parameter und Score-Systeme in der Beurteilung des Therapieerfolges bei Sepsis und septischem Schock. Infection 18:5, pages 253-262.
Crossref
S K Jackson, J Parton, G Shortland, J M Stark & E N Thompson. (1990) Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers.. Archives of Disease in Childhood 65:7, pages 771-773.
Crossref